Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
|Director, Site Quality Management||
|Clinical Project Manager||
|Sr. Manager, Regulatory Affairs - International||
|Associate - Food and Drug||
Keller and Heckman LLP
|In house Compliance Officer||
|Pompano Beach, FL|